What is New in Diagnosis of Amyloidosis?
Article Sidebar
Main Article Content
Abstract
Amyloidosis has always represented a diagnostic challenge. In 2020, the Amyloidosis Study Group (ASG) developed the "Clinical Practice Guideline for the Diagnosis of Amyloidosis". New lines of research have subsequently emerged. This narrative review aims to explore the state of the art in the diagnosis of amyloidosis diagnosis.
In patients with amyloidosis, protein typing by mass spectrometry is recommended, a technique hard to perform because it requires laser microdissection for sample preparation. Recent publications propose other methods to obtain the amyloid sample to be analyzed, making it possible to dispense with microdissection.
On the other hand, in patients with confirmed TTR amyloidosis (aTTR), the recommendation to sequence the amyloidogenic gene was intended for suspected cases of hereditary aTTR but has now been extended to all patients regardless of age.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Posadas Martinez ML, Aguirre MA, Belziti C, Brouet E, Auteri MA, Forte AL, et al. 74-82. Guía de Práctica Clínica para el diagnóstico de la amiloidosis: Parte 1/3. Año 2020. 2021 03 12. Rev Fac Cien Med Univ Nac Cordoba. 2021 Mar 12;78(1):74–82. Disponible en: https://revistas.unc.edu.ar/index.php/med/article/view/30824/33103 DOI: https://doi.org/10.31053/1853.0605.v78.n1.30824
Posadas Martinez ML, Nucifora E, Belziti C, Auteri MA, Pitzus AE, Dragonetti L, et al. Clinical Practice Guidelines for diagnosis of organic involvement of amyloidosis: Part 2/3.Year 2020. Rev Fac Cien Med Univ Nac Cordoba. 2022 Mar 7;79(1):78–87. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004298/ DOI: https://doi.org/10.31053/1853.0605.v79.n1.30897
Martinez MLP, Aguirre MA, Greloni G, Marciano S, Perez de Arenaza D, Rugiero M, et al. Guía de Práctica Clínica para el diagnóstico de compromiso orgánico en amiloidosis: Parte 3/3 Año 2020: GPC compromiso orgánico en amiloidosis. Rev Fac Cien Med Univ Nac Cordoba. 2022 Dec 21;79(4):391–9. DOI: https://doi.org/10.31053/1853.0605.v79.n4.30903
Kamiie J, Aihara N, Uchida Y, Kobayashi D, Yoshida Y, Kuroda T, Sakaue M et a. Amyloid-specific extraction using organic solvents. Methods X. 2021 Sept. Disponible en: https://doi.org/10.1016/j.mex.2019.100770 DOI: https://doi.org/10.1016/j.mex.2019.100770
Phipps WS, Smith KD, Yang HY, Henderson CM, Pflaum H, Lerch ML, et al. Tandem Mass Spectrometry-Based Amyloid Typing Using Manual Microdissection and Open-Source Data Processing. Am J Clin Pathol. 2022 May 4;157(5):748–57. DOI: https://doi.org/10.1093/ajcp/aqab185
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases [Internet]. Vol. 42, European Heart Journal. 2021. p. 1554–68. Disponible en: http://dx.doi.org/10.1093/eurheartj/ehab072. DOI: https://doi.org/10.1093/eurheartj/ehab072
Jiang S, Zhang L, Wang J, Li X, Hu S, Fu Y, et al. Differentiating between cardiac amyloidosis and hypertrophic cardiomyopathy on non-contrast cine-magnetic resonance images using machine learning-based radiomics. Front Cardiovasc Med. 2022 Oct 26;9:1001269. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643770/ DOI: https://doi.org/10.3389/fcvm.2022.1001269
Ticau S, Sridharan GV, Tsour S, Cantley WL, Chan A, Gilbert JA, et al. Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis. Neurology. 2021 Jan 19;96(3):e412–22. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33087494/ DOI: https://doi.org/10.1212/WNL.0000000000011090
Louwsma J, Brunger AF, Bijzet J, Kroesen BJ, Roeloffzen WWH, Bischof A, et al. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis. Amyloid. 2021 Mar;28(1):50–5. Disponible en: https://www.tandfonline.com/doi/full/10.1080/13506129.2020.1815696 DOI: https://doi.org/10.1080/13506129.2020.1815696
Dispenzieri A, Larson DR, Rajkumar SV, Kyle RA, Kumar SK, Kourelis T, et al. N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression. Leukemia. 2020 Oct;34(10):2749–53. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529948/ DOI: https://doi.org/10.1038/s41375-020-0940-8